ALERTS : DISTRIBUTION - ADVERTISING - PHARMACEUTICAL SPECIALTY - COMPARATIVE ADVERTISING - MISLEADING PRACTICE

Advertising: The French Supreme Court assesses the legality of an advertisement that presents a pharmaceutical specialty as a generic version of a brand-name drug (Mopral)

KEYWORDS
Reference

Cass. com., 7 juillet 2009, Astrazeneca c/ Sandoz, pourvoi n°08-11.660

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. A laboratory had published several brochures aimed at health professionals, announcing the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

This document is protected by copyright laws and international copyright treaties. Non-authorised use of this document constitutes a violation of the publisher's rights and may be punished by up to 3 years imprisonment and up to a € 300 000 fine (Art. L 335-2 Code de la Propriété Intellectuelle). Personal use of this document is authorised within the limits of Art. L 122-5 CPI and DRM protection.

PDF Version

Author

Quotation

Régis Pihéry, Advertising: The French Supreme Court assesses the legality of an advertisement that presents a pharmaceutical specialty as a generic version of a brand-name drug (Mopral), 7 July 2009, Concurrences N° 4-2009, Art. N° 29936, www.concurrences.com

Visites 2161

All reviews